Alain Zannetti

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study

Jean‐Christophe Eymard, Stéphane Oudard, Gwénaëlle Gravis et al. · British Journal of Urology · 2010 · 96 citations

Medicine, Oncology, Pharmacology +16

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier et al. · JAMA Oncology · 2021 · 81 citations · Full text

Medicine, Gynecology, Oncology +17

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

J-C. Eymard, Franck Priou, Alain Zannetti et al. · Annals of Oncology · 2007 · 55 citations · Full text

Medicine, Oncology, Pharmacology +15

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study

F. Joly, Djihane Ahmed-Lecheheb, Elsa Kalbacher et al. · Annals of Oncology · 2019 · 55 citations

Medicine, Gynecology, Oncology +10